Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small cell lung cancer, reinforcing its position as a standard-care medication.

AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about tariffs loom over the industry.

AstraZeneca (AZN) said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have announced more than $200 billion combined in investments in the coming ...

AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.

AstraZeneca reported 11% year-on-year revenue growth, excluding a 1% currency headwind, and core operating profit growth of 14%. Management reiterated its full-year guidance of high single-digit ...

AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D.This investment is expected to ...

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca announces largest ever investment in U.S. manufacturingAstraZeneca (AZN) said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...